Brokerages Set Phibro Animal Health Corporation (NASDAQ:PAHC) PT at $42.50

Shares of Phibro Animal Health Corporation (NASDAQ:PAHC) have received a consensus rating of “Hold” from the five research firms that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and one has assigned a buy recommendation to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $42.50.

Several research analysts have weighed in on PAHC shares. Citigroup reduced their target price on Phibro Animal Health from $62.00 to $44.00 and set a “neutral” rating on the stock in a report on Thursday, May 14th. Zacks Research cut Phibro Animal Health from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 21st. Wall Street Zen cut Phibro Animal Health from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. Finally, Weiss Ratings downgraded shares of Phibro Animal Health from a “buy (b-)” rating to a “hold (c+)” rating in a report on Monday, June 15th.

Hedge Funds Weigh In On Phibro Animal Health

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. raised its stake in shares of Phibro Animal Health by 0.9% in the 4th quarter. Vanguard Group Inc. now owns 1,539,593 shares of the company’s stock valued at $57,519,000 after purchasing an additional 13,884 shares during the period. State Street Corp lifted its holdings in shares of Phibro Animal Health by 5.4% in the fourth quarter. State Street Corp now owns 942,279 shares of the company’s stock valued at $35,204,000 after purchasing an additional 48,243 shares in the last quarter. Millennium Management LLC boosted its position in shares of Phibro Animal Health by 4,227.1% during the fourth quarter. Millennium Management LLC now owns 641,313 shares of the company’s stock worth $23,959,000 after buying an additional 626,492 shares during the period. Renaissance Technologies LLC boosted its position in shares of Phibro Animal Health by 5.8% during the first quarter. Renaissance Technologies LLC now owns 576,735 shares of the company’s stock worth $31,899,000 after buying an additional 31,435 shares during the period. Finally, Geode Capital Management LLC grew its holdings in shares of Phibro Animal Health by 4.0% during the fourth quarter. Geode Capital Management LLC now owns 569,111 shares of the company’s stock worth $21,265,000 after buying an additional 21,951 shares in the last quarter. 99.34% of the stock is owned by institutional investors and hedge funds.

Phibro Animal Health Stock Up 3.2%

Shares of NASDAQ:PAHC opened at $36.32 on Friday. The company has a 50 day moving average price of $33.70 and a two-hundred day moving average price of $42.61. The company has a debt-to-equity ratio of 1.97, a quick ratio of 1.26 and a current ratio of 3.17. The company has a market capitalization of $1.47 billion, a PE ratio of 15.59, a PEG ratio of 0.50 and a beta of 0.46. Phibro Animal Health has a 52 week low of $28.25 and a 52 week high of $60.08.

Phibro Animal Health Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 23rd. Investors of record on Wednesday, September 2nd will be given a $0.12 dividend. This represents a $0.48 annualized dividend and a yield of 1.3%. The ex-dividend date of this dividend is Wednesday, September 2nd. Phibro Animal Health’s payout ratio is currently 20.60%.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.